{'fraction_non_alphanumeric': 0.05573080967402734, 'fraction_numerical': 0.04311251314405889, 'mean_word_length': 4.987421383647798, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
High prevalence of genotype 4 among hepatitis C virus‐infected intravenous drug users in North‐Eastern Poland

The aim of this study was to describe the distribution of hepatitis C genotypes among intravenous drug users in north‐eastern Poland. The study group included intravenous drug users recruited at a drug treatment center and a clinic for HIV‐infected patients. HCV infection was confirmed by qualitative nested RT‐PCR to test for the presence of HCV RNA. Genotypes were determined by 5′UTR sequencing and comparing the results with known genotype sequences. Among 111 HCV‐infected and HCV–RNA‐positive intravenous drug users, the most prevalent genotypes were 1 (38.7%), 3 (37.8%), and 4 (23.4%). Most infections with genotype 4 (88.5%) were found among HCV–HIV‐coinfected drug users. The study demonstrated a high prevalence of genotype 4 (23.4%) among HCV‐infected Polish drug users. J. Med. Virol. 80:615–618, 2008. © 2008 Wiley‐Liss, Inc.